PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1954662
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1954662
The global peptide synthesis market was valued at USD 746.7 million in 2025 and is projected to grow to USD 800.16 million in 2026. The market is further expected to reach USD 1,640.52 million by 2034, registering a strong CAGR of 9.39% during the forecast period.
North America dominated the global peptide synthesis market with a 48.59% market share in 2025. Growth is driven by rising demand for peptide-based therapeutics, technological advancements in synthesis techniques, and expanding research & development investments.
Peptide synthesis involves the chemical or biological construction of short amino acid chains in a defined sequence. Modern techniques such as solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS) enable customized peptide production for therapeutic, diagnostic, and research applications.
Market Dynamics
Market Drivers
Rising Demand for Peptide-Based Drugs
One of the primary growth drivers is the increasing adoption of peptide-based drugs due to their high specificity, low toxicity, and improved safety profiles compared to small-molecule drugs. Peptides are widely used in oncology, metabolic disorders, diabetes, and rare diseases.
For instance, in August 2025, BioMed X collaborated with Novo Nordisk to develop oral formulations for peptide drugs such as GLP-1 receptor agonists. The growing pipeline of peptide therapeutics in clinical trials is significantly driving synthesis demand.
Market Restraints
Technical Limitations in Large-Scale Production
Despite strong growth, large-scale peptide synthesis faces challenges including incomplete coupling, aggregation, racemization, and high solvent consumption. Scaling SPPS from laboratory to commercial production often results in increased purification costs and reduced yields, limiting broader market expansion.
Market Opportunities
Technological Advancements in Synthesis Methods
Innovations such as microwave-assisted SPPS, hybrid SPPS-LPPS techniques, and continuous-flow synthesis are transforming peptide production efficiency. These advancements reduce solvent usage, shorten cycle times, and improve yield and purity.
For example, in April 2022, CEM Corporation launched the Liberty Blue 2.0 microwave peptide synthesizer, reducing solvent use by over 90% and enabling greener production processes.
Market Challenges
High Production and Purification Costs
Long and structurally complex peptides require multi-step synthesis and high-performance liquid chromatography (HPLC) purification, significantly increasing costs. For example, tirzepatide (Mounjaro), a 39-amino acid peptide drug, requires large-scale purification and complex production processes, contributing to higher manufacturing expenses.
Market Trends
Growing Outsourcing to CDMOs
A key trend in the market is the increasing outsourcing of peptide manufacturing to specialized Contract Development and Manufacturing Organizations (CDMOs). Pharmaceutical companies prefer outsourcing to reduce infrastructure investment and accelerate time-to-market.
In July 2024, Corden Pharma announced a €900 million (USD 1,047.2 million) investment to expand global peptide production capacity, highlighting growing outsourcing demand.
By Offering
The market is divided into products and services.
The services segment dominated the market with a 71.03% share in 2026, driven by increased outsourcing and rising demand for large-scale peptide manufacturing. In October 2025, Cambrex Corporation announced a USD 120 million investment to expand peptide manufacturing capacity in the U.S.
By Method
The market includes:
The SPPS segment dominated with a 74.42% share in 2026, owing to automation compatibility, scalability, and high efficiency. The LPPS segment is expected to grow at a CAGR of 6.45% during the forecast period.
By Application
Applications include:
The therapeutics segment held the largest share at 66.25% in 2026, driven by increasing commercialization of peptide drugs and a strong clinical pipeline. Diagnostics is projected to grow at 7.35% during the forecast period.
By End User
The market is segmented into:
Pharmaceutical & biotechnology companies dominated with a 57.1% share in 2025 and 56.94% in 2026, supported by active therapeutic innovation and strategic collaborations. The CROs & CDMOs segment is projected to grow at a CAGR of 11.62%.
North America
North America led the market with a valuation of USD 362.84 million in 2025 and is projected to reach USD 389.08 million in 2026. The U.S. market alone is expected to reach USD 360.76 million by 2026, driven by strong biopharmaceutical R&D and strategic collaborations.
Europe
Europe is projected to grow at a CAGR of 8.72% and recorded USD 160.1 million in 2025. France recorded USD 24.1 million in 2025, while the UK and Germany are projected to reach USD 39.74 million and USD 35.84 million respectively by 2026.
Asia Pacific
Asia Pacific reached USD 140.4 million in 2025. By 2026, Japan is projected to reach USD 49.53 million, China USD 30.01 million, and India USD 29.26 million.
Latin America & Middle East & Africa
Latin America recorded USD 35.0 million in 2025, while GCC countries reached USD 18.4 million in 2025. Growth in these regions is supported by expanding R&D activities.
Competitive Landscape
The market is semi-consolidated with key players including:
Strategic collaborations and technology upgrades strengthen competitive positioning. For instance, in May 2025, PeptiSystems partnered with Asahi Kasei Bioprocess America to enhance peptide synthesis technologies.
Conclusion
The global peptide synthesis market, valued at USD 746.7 million in 2025, is projected to grow to USD 800.16 million in 2026 and reach USD 1,640.52 million by 2034, expanding at a CAGR of 9.39%. Growth is primarily driven by rising demand for peptide-based therapeutics, technological advancements in SPPS and LPPS, and increasing outsourcing to CDMOs. Although high production costs and large-scale synthesis challenges remain, expanding R&D investments and innovative synthesis platforms are expected to sustain strong market growth through 2034.
Segmentation By Offering, Method, Application, End User, and Region
By Offering * Products
By Method * Liquid-Phase Peptide Synthesis
By Application * Therapeutics
By End User * Pharmaceutical & Biotechnology Companies
By Region * North America (By Offering, Method, Application, End User, and Country)